Prefer Sun Pharmaceutical Industries: Nischal Maheshwari

Nischal Maheshwari, Head-Research at Edelweiss Securities told CNBC-TV18, "I think except for technical reaction there is nothing negative on Sun Pharmaceutical Industries per se. There is going to be overhang of USD 3 billion worth of stock which has come into the market but that is going to get absorbed in the next couple of quarters and the numbers will continue to remain strong for Sun Pharma."

"I believe this is a good opportunity and technically you are getting a stock almost down 15 percent from the top," he added.